


Cascata coagulativa

Regolazione Naturale

Tissue pathway factor inhibitor (TFPI)

Disolfuro Isomerasi (PDI)



SISTEMI ANTICOAGULANTI NATURALI

Effettore

Target

**Inibitore del fattore
tissutale (TFPI)**

FVIIa-FT


**Sistema Antitrombina-
eparina**

**Enzimi (XIIa, XIa,
IXa, Xa, IIa, VIIa)**


Sistema della Proteina C

**Cofattori attivati
(VIIIa, Va)**

Rapporti tra superficie endoteliale e sangue circolante




TFPI-Xa, inibitore di VIIa-FT



VIIa-TF

TFPI-Xa



DNA

**A DNA template was synthesized with the sequence 5'-
GGAGGGAAAAGTTATCAGGC-N40-
GATTAGTTTTGGAGTACTCGCTCC-3'**

**“N40” =40-nucleotide sequence in which there is an
equal probability of incorporating a dA, dC, dG, or dT
residue at each position and**

“d” = 2'-H residue

**The DNA template was amplified by polymerase chain
reaction (PCR) with forward primer 5'-
GACTGTAATACGACTCACTATAGGAGGGAAAAG
TTATC-AGGC-3' and reverse primer 5'-
GGAGCGAGTACTCCAAAATAATC-3'**

RNA -selection

- **Transcribed** to generate a starting pool of approximately 10^{14} different sequences comprised of mA, mG, and mU residues,

“m” = 2'-OCH₃ residue

11 rounds of selection were carried out by first incubating the pool of molecules with recombinant full-length TFPI **The round 11 pool was cloned and sequenced.**

- Individual clones were generated by chemical synthesis
- Clones were tested for binding to recombinant TFPI with a nitrocellulose dot blot binding assay and for inhibition of TFPI

the clone


(5'-mGmGmAmGmGmGmAmAmAmAmGmUmUmA-mUdCmAmGmGdCdCmUmGmAmAmUmUmUmGmGmAmAmUmAmUmAdCmUmUmGmGdCmUdCmGmUmUmAmGmGmUmGdCmGmUmAmUmAmUmAmGmAmUmUmAmGmUmUmUmUmGmGmAmGmUmAdCmUdCmGdCmUdCdC-3')

was determined **to bind to TFPI with nanomolar affinity and inhibit its activity in plasma at nanomolar concentrations.**

Synthesis modification

- The core aptamer motif, **ARC17480**, was identified by design of molecules that contained a portion of the parent clone sequence and evaluation in the same assays.
- The core aptamer was synthesized with a hexylamine linker $-\text{CH}_3(\text{CH}_2)_5\text{NH}_2-$ at the 5'-end
- which was conjugated postsynthetically to a branched 40 kDa PEG moiety - $(\text{HO}-\text{CH}_2-(\text{CH}_2-\text{O}-\text{CH}_2-)_n-\text{CH}_2-\text{OH})$ - to give rise to **ARC19499**.


ARC17480 binding to TFPI and other proteins.



Waters E K et al. Blood 2011;117:5514-5522


Activity of ARC19499 in TFPI-dependent assays using purified proteins.

A



Waters E K et al. Blood 2011;117:5514-5522


ARC19499 inhibition of TFPI in human plasma.



Waters E K et al. Blood 2011;117:5514-5522

ARC19499 inhibition of TFPI in human plasma.


TFPI-depleted plasma



Waters E K et al. Blood 2011;117:5514-5522

ARC19499 effect on thrombin generation in human plasma.

Activity in hemophilia A plasma



Normal plasma (solid lines)

Hemophilia (dashed lines)


+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522

ARC19499 effect on thrombin generation in human plasma.

Activity in hemophilia B plasma



Hemophilia B+ aptamer
normal plasma

Hemophilia B

Normal plasma (solid lines)

Hemophilia (dashed lines)


+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522

ARC19499 effect on thrombin generation in human plasma.

Activity in plasma with antibody inhibitor



Normal plasma (solid lines)

Hemophilia (dashed lines)

+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522

ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion

by Jolanta M. Siller-Matula, Yahye Merhi, Jean-François Tanguay, Daniel Duerschmied, Denisa D. Wagner, Kathleen E. McGinness, P. Shannon Pendergrast, Jou-Ku Chung, Xianbin Tian, Robert G. Schaub, and Bernd Ilma


*Arterioscler Thromb Vasc Biol
Volume 32(4):902-909
March 14, 2012*

Dimerization and multimerization of VWF



Monomer
 0.25×10^6 Da

> 30 monomers !!



Dimer
 0.5×10^6 Da




Tetramer
 1.0×10^6 Da



Hexamer
 1.5×10^6 Da




Multimer
 $\geq 7.5 \times 10^6$ Da



The VWF A1-GPIIb α complex.

VWF A1 domain



Platelet
GPIIb α receptor

Mark A. Blenner et al. J. Biol. Chem. 2014;289:5565-5579

NH₂-mGmGmGmAmCmCmUmAmAmGmAmCmAmCmAmUm
GmUmCmCmC-3T, where
NH₂ = hexylamine linker,
3T inverted deoxythymidine residue
mN is a 2'-methoxy residue.

ARC15105 are appended with a 20-kDa







Figure 2. Chemical structures of 2'-modified nucleotides used in selection experiments to generate aptamers with enhanced pharmacokinetic properties: 2'-amino-NTPs **1**, 2'-fluoro-NTPs **2**, 2'-methoxy-NTPs **3**, and 4'-thio-NTPs **4**.

Platelet aggregation to ARC15105 (1.3 $\mu\text{mol/L}$) induced by various agonists: A, ADP (adenosine diphosphate); B, TRAP (thrombin receptor activating peptide); C, ristocetin; D, AA (arachidonic acid); E, collagen.




Siller-Matula J et al. Arterioscler Thromb Vasc Biol
2012;32:902-909

Concentration effect curve of ARC15105 and ARC1779 on platelet adhesion to collagen-bound VWF under arterial shear conditions.




Siller-Matula J et al. Arterioscler Thromb Vasc Biol
2012;32:902-909

Platelet adhesion on injured porcine arterial segments; A, ARC15105, Arc1779, and abciximab inhibited the adhesion of platelets radiolabeled with ^{111}In on injured porcine arterial segments in perfusion flow chambers.




Platelet adhesion on injured porcine arterial segments; A, ARC15105, Arc1779, and abciximab inhibited the adhesion of platelets radiolabeled with ¹¹¹In on injured porcine arterial segments in perfusion flow chambers.



Siller-Matula J et al. Arterioscler Thromb Vasc Biol
2012;32:902-909

Comparison of the pharmacokinetics of a single bolus of ARC15105 (20 mg/kg) administered intravenously (IV) and subcutaneously (SC) in 3 cynomolgus monkeys; P<0.05.



Siller-Matula J et al. Arterioscler Thromb Vasc Biol
2012;32:902-909